Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease

Huntington disease is a genetic neurodegenerative disorder that produces motor, neuropsychiatric, and cognitive deficits and is caused by an abnormal expansion of the CAG tract in the huntingtin (htt) gene. In humans, mutated htt induces a preferential loss of medium spiny neurons in the striatum and, to a lesser extent, a loss of cortical neurons as the disease progresses. The mechanisms causing these degenerative changes remain unclear, but they may involve synaptic dysregulation. We examined the activity of the corticostriatal pathway using a combination of electrophysiological and optical imaging approaches in brain slices and acutely dissociated neurons from the YAC128 mouse model of Huntington disease. The results demonstrated biphasic age-dependent changes in corticostriatal function. At 1 month, before the behavioral phenotype develops, synaptic currents and glutamate release were increased. At 7 and 12 months, after the development of the behavioral phenotype, evoked synaptic currents were reduced. Glutamate release was decreased by 7 months and was markedly reduced by 12 months. These age-dependent alterations in corticostriatal activity were paralleled by a decrease in dopamine D2 receptor modulation of the presynaptic terminal. Together, these findings point to dynamic alterations at the corticostriatal pathway and emphasize that therapies directed toward preventing or alleviating symptoms need to be specifically designed depending on the stage of disease progression.

[1]  W. Betz,et al.  Optical analysis of synaptic vesicle recycling at the frog neuromuscular junction. , 1992, Science.

[2]  Hui Zhang,et al.  Heterosynaptic Dopamine Neurotransmission Selects Sets of Corticostriatal Terminals , 2004, Neuron.

[3]  C. Stevens,et al.  Estimates for the pool size of releasable quanta at a single central synapse and for the time required to refill the pool. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Young Huntingtin in health and disease. , 2003, The Journal of clinical investigation.

[5]  C. Cepeda,et al.  Alterations in N‐methyl‐D‐aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease , 2005, Journal of neuroscience research.

[6]  Carlos Cepeda,et al.  Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. , 2006, Journal of neurophysiology.

[7]  R. Schneggenburger,et al.  Presynaptic Capacitance Measurements and Ca2+ Uncaging Reveal Submillisecond Exocytosis Kinetics and Characterize the Ca2+ Sensitivity of Vesicle Pool Depletion at a Fast CNS Synapse , 2003, The Journal of Neuroscience.

[8]  T. Sejnowski,et al.  [Letters to nature] , 1996, Nature.

[9]  A. Reiner,et al.  Evidence for Differential Cortical Input to Direct Pathway versus Indirect Pathway Striatal Projection Neurons in Rats , 2004, The Journal of Neuroscience.

[10]  M. Mayer,et al.  Structural determinants of allosteric regulation in alternatively spliced AMPA receptors , 1995, Neuron.

[11]  M. Hayden,et al.  Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.

[12]  A. Buisson,et al.  Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  G. Gerhardt,et al.  Microdialysis studies of basal levels and stimulus-evoked overflow of dopamine and metabolites in the striatum of young and aged Fischer 344 rats , 1999, Brain Research.

[14]  Stephen J. Smith,et al.  The kinetics of synaptic vesicle recycling measured at single presynaptic boutons , 1993, Neuron.

[15]  J. Penney,et al.  Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity‐akinesia , 1990, Annals of neurology.

[16]  He Li,et al.  Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. , 2003, Human molecular genetics.

[17]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Raymond,et al.  Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load , 2007, The Journal of physiology.

[19]  S. Lipton,et al.  Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.

[20]  Charles J. Wilson,et al.  Spontaneous subthreshold membrane potential fluctuations and action potential variability of rat corticostriatal and striatal neurons in vivo. , 1997, Journal of neurophysiology.

[21]  Robert C. Malenka,et al.  Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models , 2007, Nature.

[22]  G. Gerhardt,et al.  Age-related changes in the capacity, rate, and modulation of dopamine uptake within the striatum and nucleus accumbens of Fischer 344 rats: an in vivo electrochemical study. , 1999, The Journal of pharmacology and experimental therapeutics.

[23]  John A Dani,et al.  Selective Dopamine Filter of Glutamate Striatal Afferents , 2004, Neuron.

[24]  R. Wightman,et al.  Catecholamine exocytosis is diminished in R6/2 Huntington’s disease model mice , 2007, Journal of neurochemistry.

[25]  Michael V. Johnston,et al.  Physiological and pathophysiological roles of excitatory amino acids during central nervous system development , 1990, Brain Research Reviews.

[26]  K. Tóth,et al.  Afferent-specific innervation of two distinct AMPA receptor subtypes on single hippocampal interneurons , 1998, Nature Neuroscience.

[27]  P. Calabresi,et al.  Vulnerability of Medium Spiny Striatal Neurons to Glutamate: Role of Na+/K+ ATPase , 1995, The European journal of neuroscience.

[28]  C. Cepeda,et al.  Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. , 1998, Journal of neurophysiology.

[29]  P. Brundin,et al.  Synaptic dysfunction in Huntington’s disease: a new perspective , 2005, Cellular and Molecular Life Sciences CMLS.

[30]  Patrik Brundin,et al.  Huntington's disease: a synaptopathy? , 2003, Trends in molecular medicine.

[31]  C. Cepeda,et al.  Repeated Exposure to Methamphetamine Causes Long-Lasting Presynaptic Corticostriatal Depression that Is Renormalized with Drug Readministration , 2008, Neuron.

[32]  R. Wightman,et al.  Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease , 2006, Journal of neurochemistry.

[33]  C. Cepeda,et al.  NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.

[34]  E. Simpson,et al.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.

[35]  Carlos Cepeda,et al.  Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.

[36]  J. Penney,et al.  Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis , 1995, Neuroscience.

[37]  J. Isaacson,et al.  GABAB-Mediated Presynaptic Inhibition of Excitatory Transmission and Synaptic Vesicle Dynamics in Cultured Hippocampal Neurons , 1997, Neuron.

[38]  J. Isaacson,et al.  GABA(B)-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons. , 1997, Neuron.

[39]  Carlos Cepeda,et al.  Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.

[40]  Roger L Albin,et al.  Longitudinal Evaluation of the Hdh (CAG)150 Knock-In Murine Model of Huntington's Disease , 2007, The Journal of Neuroscience.

[41]  B. Harper Huntington Disease , 2005, Journal of the Royal Society of Medicine.

[42]  R. Albin,et al.  Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers , 2001, Synapse.

[43]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[44]  G. Hardingham,et al.  The Dichotomy of NMDA Receptor Signaling , 2007, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[45]  M. Chesselet,et al.  Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. , 2001, Journal of neurophysiology.

[46]  P. Garris,et al.  Sub-second changes in accumbal dopamine during sexual behavior in male rats , 2001, Neuroreport.

[47]  H. Haas,et al.  Differential modulation of AMPA receptors by cyclothiazide in two types of striatal neurons , 2000, The European journal of neuroscience.

[48]  M. Mayer,et al.  Cyclothiazide differentially modulates desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor splice variants. , 1994, Molecular pharmacology.

[49]  Timothy H Murphy,et al.  Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. , 2004, Journal of neurophysiology.

[50]  S. W. Davies,et al.  Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  C. Cepeda,et al.  Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.

[52]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[53]  J. Penney,et al.  Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. , 1999, Journal of neuropathology and experimental neurology.

[54]  M. Hayden,et al.  Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s disease , 2007, Neuroscience.

[55]  C. Nicholson,et al.  Amphetamine Distorts Stimulation-Dependent Dopamine Overflow: Effects on D2 Autoreceptors, Transporters, and Synaptic Vesicle Stores , 2001, The Journal of Neuroscience.

[56]  B. Sakmann,et al.  Imaging Synaptic Activity in Intact Brain and Slices with FM1-43 in C. elegans, Lamprey, and Rat , 1999, Neuron.

[57]  Marian DiFiglia,et al.  Excitotoxic injury of the neostriatum: a model for Huntington's disease , 1990, Trends in Neurosciences.

[58]  E. Richfield,et al.  Reduced expression of preproenkephalin in striatal neurons from huntington's disease patients , 1995, Annals of neurology.

[59]  D. Sibley,et al.  Striatal neurochemical changes in transgenic models of Huntington's disease , 2002, Journal of neuroscience research.

[60]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[61]  R. Palmiter,et al.  Dopamine Modulates Release from Corticostriatal Terminals , 2004, The Journal of Neuroscience.

[62]  Max Kleiman-Weiner,et al.  Differential electrophysiological properties of dopamine D1 and D2 receptor‐containing striatal medium‐sized spiny neurons , 2008, The European journal of neuroscience.

[63]  Carlos Cepeda,et al.  The corticostriatal pathway in Huntington's disease , 2007, Progress in Neurobiology.

[64]  Steven A. Siegelbaum,et al.  Visualization of changes in presynaptic function during long-term synaptic plasticity , 2001, Nature Neuroscience.

[65]  K. Svoboda,et al.  Two-photon imaging in living brain slices. , 1999, Methods.

[66]  Scott H Chandler,et al.  Striatal potassium channel dysfunction in Huntington's disease transgenic mice. , 2005, Journal of neurophysiology.

[67]  J. Bargas,et al.  Cellular and molecular characterization of Ca2+ currents in acutely isolated, adult rat neostriatal neurons , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[68]  L. Raymond,et al.  Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease , 2006, Neurobiology of Disease.